This is part II in a series of letters to my Doctor.
At our meeting today, you expressed concern that my HbA1c number was too low, that in fact, you thought it was dangerously low and that it might lead to a heart attack. My "low" HbA1c number (which, according to you, means less than 6.5) is still not in the "normal" range. I am still at risk for organ damage because the number is too high, and yet you are concerned.
I believe you are mistaken. I have learned more about managing diabetes from a romance novelist (whose books have "bodice ripper" covers) named Jenny Ruhl (nom de plume: Jenny Brown) than from anyone with an M.D., Ph.D., R.N., R.D., or C.D.E. behind their names. She has thoroughly examined and ripped a part the ACCORD study, from whence came the idea that an HbA1c reading lower than 6.5 is dangerous, in several different places. The basic problem: the study participants took Avandia, a drug known to cause heart attacks (it was withdrawn from the market). So is it lowering the HbA1c that is dangerous, or the drug they were taking? She lists other problems with the study and even has a list of seven questions to ask physicians when they suggest that your HbA1c is too low. You may want to ask yourself all of these questions, as they might cause you to reconsider your recommendation. So I won't repeat all of that information here for you, as I know you have an Internet connection as well.
But it might be useful for you to read the statement published in the June 2011 issue of the New England Journal of Medicine. Here is an excerpt from that statement (again, that previously mentioned romance novelist alerted me to this editorial):
44.7% of subjects in the intensive-therapy group, as compared with 25.2% in the standard-therapy group, received rosiglitazone [Avandia] just before the study transition date. According to the 2008 article summarizing the results of the ACCORD trial up to the point of protocol transition, 91.2% of the subjects in the intensive-therapy group, as compared with 57.5% of the patients in the standard-therapy group, had received rosiglitazone...
Although other differences in drug exposure warrant further analysis, we think that the authors [of the ACCORD publications] should consider (and address in a secondary analysis) the role of rosiglitazone in the excess deaths from cardiovascular causes, especially in the absence of biologic plausibility of a glucose-mediated effect. Given unbalanced exposure, we thing that the ACCORD trial is inconclusive and that the recommendation to abandon lower glucose targets is not supported and has unknown consequences for the long-term management of diabetes [emphasis added].
The letter was signed by several prominent researchers and this casts considerable doubt on the idea that a score below 6.5 is dangerous.
In addition, I am a type II diabetic, not type I, and I have never suffered from hypoglycemia. My problem is hyperglycemia, and there is a huge difference. Plus, unlike some of the study participants, I haven't ignored type II diabetes for thirty years (and all of the complications that come with ignoring the disease for that long). I am grabbing hold of my health and making the changes for a more healthy way of living.
So might I suggest that lowering my HbA1c to a level between 5.0 and 5.9 is an appropriate goal for me? I have no wish to suffer any complications of diabetes because you think my HbA1c score is too low.